Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.
Glatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying the cardiovascular side effects of the medication are unclear. Here, we made use of the chromosomal variation in the ge...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5567477?pdf=render |
| _version_ | 1819083377587781632 |
|---|---|
| author | Ingrid Brænne Lingyao Zeng Christina Willenborg Vinicius Tragante Thorsten Kessler CARDIoGRAM Consortium CARDIoGRAMplusC4D Consortium Cristen J Willer Markku Laakso Lars Wallentin Paul W Franks Veikko Salomaa Abbas Dehghan Thomas Meitinger Nilesh J Samani Folkert W Asselbergs Jeanette Erdmann Heribert Schunkert |
| author_facet | Ingrid Brænne Lingyao Zeng Christina Willenborg Vinicius Tragante Thorsten Kessler CARDIoGRAM Consortium CARDIoGRAMplusC4D Consortium Cristen J Willer Markku Laakso Lars Wallentin Paul W Franks Veikko Salomaa Abbas Dehghan Thomas Meitinger Nilesh J Samani Folkert W Asselbergs Jeanette Erdmann Heribert Schunkert |
| author_sort | Ingrid Brænne |
| collection | DOAJ |
| description | Glatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying the cardiovascular side effects of the medication are unclear. Here, we made use of the chromosomal variation in the genes that are known to be affected by glatiramer treatment. Focusing on genes and gene products reported by drug-gene interaction database to interact with glatiramer acetate we explored a large meta-analysis on CAD genome-wide association studies aiming firstly, to investigate whether variants in these genes also affect cardiovascular risk and secondly, to identify new CAD risk genes. We traced association signals in a 200-kb region around genomic positions of genes interacting with glatiramer in up to 60 801 CAD cases and 123 504 controls. We validated the identified association in additional 21 934 CAD cases and 76 087 controls. We identified three new CAD risk alleles within the TGFB1 region on chromosome 19 that independently affect CAD risk. The lead SNP rs12459996 was genome-wide significantly associated with CAD in the extended meta-analysis (odds ratio 1.09, p = 1.58×10-12). The other two SNPs at the locus were not in linkage disequilibrium with the lead SNP and by a conditional analysis showed p-values of 4.05 × 10-10 and 2.21 × 10-6. Thus, studying genes reported to interact with glatiramer acetate we identified genetic variants that concordantly with the drug increase the risk of CAD. Of these, TGFB1 displayed signal for association. Indeed, the gene has been associated with CAD previously in both in vivo and in vitro studies. Here we establish genome-wide significant association with CAD in large human samples. |
| first_indexed | 2024-12-21T20:31:36Z |
| format | Article |
| id | doaj.art-73eeb4fe985946ec82b07e430312a6f3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T20:31:36Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-73eeb4fe985946ec82b07e430312a6f32022-12-21T18:51:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01128e018299910.1371/journal.pone.0182999Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.Ingrid BrænneLingyao ZengChristina WillenborgVinicius TraganteThorsten KesslerCARDIoGRAM ConsortiumCARDIoGRAMplusC4D ConsortiumCristen J WillerMarkku LaaksoLars WallentinPaul W FranksVeikko SalomaaAbbas DehghanThomas MeitingerNilesh J SamaniFolkert W AsselbergsJeanette ErdmannHeribert SchunkertGlatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying the cardiovascular side effects of the medication are unclear. Here, we made use of the chromosomal variation in the genes that are known to be affected by glatiramer treatment. Focusing on genes and gene products reported by drug-gene interaction database to interact with glatiramer acetate we explored a large meta-analysis on CAD genome-wide association studies aiming firstly, to investigate whether variants in these genes also affect cardiovascular risk and secondly, to identify new CAD risk genes. We traced association signals in a 200-kb region around genomic positions of genes interacting with glatiramer in up to 60 801 CAD cases and 123 504 controls. We validated the identified association in additional 21 934 CAD cases and 76 087 controls. We identified three new CAD risk alleles within the TGFB1 region on chromosome 19 that independently affect CAD risk. The lead SNP rs12459996 was genome-wide significantly associated with CAD in the extended meta-analysis (odds ratio 1.09, p = 1.58×10-12). The other two SNPs at the locus were not in linkage disequilibrium with the lead SNP and by a conditional analysis showed p-values of 4.05 × 10-10 and 2.21 × 10-6. Thus, studying genes reported to interact with glatiramer acetate we identified genetic variants that concordantly with the drug increase the risk of CAD. Of these, TGFB1 displayed signal for association. Indeed, the gene has been associated with CAD previously in both in vivo and in vitro studies. Here we establish genome-wide significant association with CAD in large human samples.http://europepmc.org/articles/PMC5567477?pdf=render |
| spellingShingle | Ingrid Brænne Lingyao Zeng Christina Willenborg Vinicius Tragante Thorsten Kessler CARDIoGRAM Consortium CARDIoGRAMplusC4D Consortium Cristen J Willer Markku Laakso Lars Wallentin Paul W Franks Veikko Salomaa Abbas Dehghan Thomas Meitinger Nilesh J Samani Folkert W Asselbergs Jeanette Erdmann Heribert Schunkert Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. PLoS ONE |
| title | Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. |
| title_full | Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. |
| title_fullStr | Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. |
| title_full_unstemmed | Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. |
| title_short | Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. |
| title_sort | genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk |
| url | http://europepmc.org/articles/PMC5567477?pdf=render |
| work_keys_str_mv | AT ingridbrænne genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT lingyaozeng genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT christinawillenborg genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT viniciustragante genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT thorstenkessler genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT cardiogramconsortium genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT cardiogramplusc4dconsortium genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT cristenjwiller genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT markkulaakso genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT larswallentin genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT paulwfranks genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT veikkosalomaa genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT abbasdehghan genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT thomasmeitinger genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT nileshjsamani genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT folkertwasselbergs genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT jeanetteerdmann genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk AT heribertschunkert genomiccorrelatesofglatirameracetateadversecardiovasculareffectsleadtoanovellocusmediatingcoronaryrisk |